Heddle Jonathan, Maxwell Anthony
Department of Biochemistry, University of Leicester, Leicester LE1 7RH, United Kingdom.
Antimicrob Agents Chemother. 2002 Jun;46(6):1805-15. doi: 10.1128/AAC.46.6.1805-1815.2002.
DNA gyrase is a prokaryotic type II topoisomerase and a major target of quinolone antibacterials. The majority of mutations conferring resistance to quinolones arise within the quinolone resistance-determining region of GyrA close to the active site (Tyr(122)) where DNA is bound and cleaved. However, some quinolone resistance mutations are known to exist in GyrB. Present structural data suggest that these residues lie a considerable distance from the quinolone resistance-determining region, and it is not obvious how they affect quinolone action. We have made and purified two such mutant proteins, GyrB(Asp(426)-->Asn) and GyrB(Lys(447)-->Glu), and characterized them in vitro. We found that the two proteins behave similarly to GyrA quinolone-resistant proteins. We showed that the mutations exert their effect by decreasing the amount of quinolone bound to a gyrase-DNA complex. We suggest that the GyrB residues form part of a quinolone-binding pocket that includes DNA and the quinolone resistance-determining region in GyrA and that large conformational changes during the catalytic cycle of the enzyme allow these regions to come into close proximity.
DNA促旋酶是一种原核II型拓扑异构酶,也是喹诺酮类抗菌药物的主要作用靶点。大多数赋予喹诺酮耐药性的突变发生在靠近活性位点(Tyr(122))的GyrA喹诺酮耐药决定区,DNA在此结合并被切割。然而,已知一些喹诺酮耐药突变存在于GyrB中。目前的结构数据表明,这些残基距离喹诺酮耐药决定区相当远,它们如何影响喹诺酮作用尚不清楚。我们制备并纯化了两种这样的突变蛋白,GyrB(Asp(426)-->Asn)和GyrB(Lys(447)-->Glu),并对其进行了体外特性研究。我们发现这两种蛋白的行为与GyrA喹诺酮耐药蛋白相似。我们表明,这些突变通过减少与促旋酶-DNA复合物结合的喹诺酮量来发挥作用。我们认为,GyrB残基构成了一个喹诺酮结合口袋的一部分,该口袋包括DNA和GyrA中的喹诺酮耐药决定区,并且在酶的催化循环过程中发生的大的构象变化使这些区域紧密靠近。